The average clinical research site converts two to four percent of its website visitors into inquiries on the first visit. That means 96 to 98 percent of patients who found your site, showed enough interest to click, read some information, and left — without ever making contact. Retargeting campaigns are built specifically to re-engage that majority: patients who expressed interest through their visit behavior but did not take the final step of submitting an inquiry.
How Retargeting Works for Research Sites
Retargeting works by placing a small piece of tracking code (a pixel) on your website that adds visitors to custom audience lists. When those visitors go to Google, Facebook, Instagram, or other ad networks, they see ads from your site. The ad is not random — it is shown specifically because the patient previously visited a relevant page on your site, making the message contextually relevant in a way cold advertising cannot replicate.
For clinical research sites, create separate retargeting audiences based on which pages visitors viewed. A patient who visited the trial-specific page for your diabetes study is more valuable to retarget with diabetes-specific messaging than with a generic research site ad. A patient who visited your pre-screening form but did not submit it is the highest-priority retargeting audience — they were one step from converting, and a well-timed retargeting ad with a specific call to action or an additional trust element (a review quote, a compensation reminder) can recover that conversion.
Retargeting Audience Segmentation for Maximum ROI
Segment your retargeting audiences into at least three tiers based on visit engagement. Tier one is high-intent visitors: patients who visited a specific trial page, spent more than 60 seconds on the site, or reached the pre-screening form. These audiences receive the most specific, conversion-focused retargeting creative and the highest budget allocation. Tier two is medium-intent visitors: patients who visited multiple pages or the homepage and at least one internal page. These audiences receive educational creative that answers common eligibility and participation questions. Tier three is low-intent visitors: patients who visited one page and left quickly. These audiences receive broad awareness creative and the lowest budget allocation.
Exclude converted patients — anyone who has already submitted an inquiry form — from all retargeting audiences. Showing conversion-focused ads to patients who have already converted wastes budget and creates a confusing experience for patients who are already in your pipeline. Set exclusion windows that cover the full length of your expected inquiry-to-enrollment timeline.
Retargeting Creative and Frequency Caps
Retargeting creative should be different from your cold audience creative. It can reference the patient’s prior visit implicitly — “Still thinking about the [condition] study?” — and address the most common objections that prevent visitors from converting: concerns about time commitment, eligibility uncertainty, or safety questions. Provide a specific answer to each objection in the ad creative and link to a landing page that expands on that answer before presenting the inquiry form.
Set frequency caps on retargeting campaigns to prevent ad fatigue. A patient who sees your retargeting ad 20 times in three days without converting is not going to convert from the 21st impression — they are going to develop negative associations with your site. Limit retargeting frequency to three to five impressions per user per day across all platforms combined. Set a retargeting window of 30 to 60 days — patients who visited more than 60 days ago and have not yet inquired are unlikely to convert from further retargeting and should be removed from active audiences.
Retargeting is consistently the highest-ROI component of a clinical trial advertising portfolio. The audiences it targets have already demonstrated interest, which means the cost to convert them into inquiries is a fraction of the cost to generate the same inquiry from a cold audience. Every research site running paid advertising without retargeting is leaving a significant percentage of its potential patient inquiries unrealized.